Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy.
The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself.
Future controlled studies are needed to confirm these potential benefits in patients considered to be unresponsive to Sativex, based on changes in a spasticity scale.
Click here to read full article https://multiplesclerosisnewstoday.com/news-posts/2020/04/27/effects-of-thccbd-oromucosal-spray-on-spasticity-related-symptoms-in-people-with-multiple-sclerosis-results-from-a-retrospective-multicenter-study/
